[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Arevalo et al., 2024 - Google Patents

Using Dry Dispersion Laser Diffraction to Assess Dispersibility in Spheronized Agglomerate Formulations

Arevalo et al., 2024

Document ID
16380595013067220204
Author
Arevalo F
Tignor S
Brunskill A
Goodey A
Publication year
Publication venue
AAPS PharmSciTech

External Links

Snippet

In this study, dry dispersion laser diffraction was used to study the dispersibility of spheronized agglomerate formulations and identify geometric particle size metrics that correlated well with aerodynamic particle size distribution (APSD). Eleven unique batches of …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Similar Documents

Publication Publication Date Title
Guenette et al. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design
Buttini et al. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers
Jaffari et al. Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction
DK2178500T3 (en) Dry powder drug-
Kaialy et al. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate
Zhou et al. Drug–lactose binding aspects in adhesive mixtures: Controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces
Pilcer et al. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations
Ramachandran et al. Formulation pre-screening of inhalation powders using computational atom–atom systematic search method
Adi et al. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations
Johal et al. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE study
Otake et al. Inhalable spray-freeze-dried powder with L-leucine that delivers particles independent of inspiratory flow pattern and inhalation device
Jetzer et al. Probing the particulate microstructure of the aerodynamic particle size distribution of dry powder inhaler combination products
Shur et al. Effect of device design and formulation on the in vitro comparability for multi-unit dose dry powder inhalers
Zhu et al. Analysis of the influence of relative humidity on the moisture sorption of particles and the aerosolization process in a dry powder inhaler
Ung et al. In vitro assessment of dose delivery performance of dry powders for inhalation
Ung et al. Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose
Ziffels et al. In vitro dry powder inhaler formulation performance considerations
Traini et al. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers
Khatri et al. An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions
Hoe et al. The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers
Stein Estimating the number of droplets and drug particles emitted from MDIs
Arevalo et al. Using Dry Dispersion Laser Diffraction to Assess Dispersibility in Spheronized Agglomerate Formulations
Mehta et al. Exploring the impact of extrinsic lactose fines, a USP modified sampling device and modified centrifuge tube on the delivered dose uniformity and drug detachment performance of a fluticasone propionate dry powder inhaler
Mehta et al. Probing the influence of lactose fines, a USP modified induction port and modified DDU apparatus on the aerodynamic behavior of a fluticasone propionate dry powder inhaler
Jones et al. High-pressure aerosol suspensions—A novel laser diffraction particle sizing system for hydrofluoroalkane pressurised metered dose inhalers